---
document_datetime: 2025-12-02 04:52:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ondexxya.html
document_name: ondexxya.html
version: success
processing_time: 0.1094171
conversion_datetime: 2025-12-24 17:37:51.302185
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ondexxya

[RSS](/en/individual-human-medicine.xml/67199)

##### Authorised

This medicine is authorised for use in the European Union

andexanet alfa Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ondexxya](#news-on)
- [More information on Ondexxya](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ondexxya is a medicine used for stopping life-threatening or uncontrolled bleeding in adults taking the anticoagulant medicines apixaban or rivaroxaban.

Ondexxya contains the active substance andexanet alfa.

Expand section

Collapse section

## How is Ondexxya used?

Ondexxya can only be obtained with a prescription and it must be used in hospital only.

Ondexxya is given by infusion (drip) into a vein over about 2.5 hours. The dose depends on what the last dose of the anticoagulant was and when the patient took it.

For more information about using Ondexxya, see the package leaflet or contact your doctor or pharmacist.

## How does Ondexxya work?

Andexanet alfa, the active substance in Ondexxya, acts as a decoy target for anticoagulants called factor Xa inhibitors such as apixaban and rivaroxaban. These anticoagulants work by blocking factor Xa, a natural protein that helps the blood to clot. When Ondexxya is given, the anticoagulants attach to andexanet alfa instead, and they are no longer available to block factor Xa. As a result, the excessive bleeding caused by the anticoagulants is reduced.

## What benefits of Ondexxya have been shown in studies?

Two main studies have found Ondexxya effective in healthy volunteers who took either apixaban or rivaroxaban, two anticoagulants that block the effect of factor Xa.

The main measure of effectiveness was the reduction in 'antifactor Xa activity' (a measure of how well natural factor Xa is blocked by an anticoagulant). In the first study, involving people who had taken apixaban, the full dose of Ondexxya reduced antifactor Xa activity by 92% on average in 23 people compared with 33% in 8 people receiving placebo (a dummy treatment). In the second study,

involving people who had taken rivaroxaban, the full dose of Ondexxya reduced antifactor Xa activity by 97% on average in 26 people, compared with 45% in 13 people receiving placebo.

A further ongoing study involved patients taking a factor Xa inhibitor anticoagulant who had major bleeding. After treatment with Ondexxya, antifactor Xa activity was reduced on average by 90% in 83 patients taking apixaban and by 78% in 70 patients taking rivaroxaban.

## What are the risks associated with Ondexxya?

Based on studies in healthy volunteers, the most common side effects with Ondexxya (which may affect more than 1 in 10 people) are flushing, feeling hot, both of which are related to infusing the medicine, and a short-lived increase in levels of certain proteins indicating blood clotting. In patients who were bleeding, the most common side effects (affecting around 1 in 10 people) were thromboembolism (problems due to clots in blood vessels such as blocked veins, heart attack and stroke) and fever.

Ondexxya must not be used in patients who are allergic to hamster proteins. For the full list of side effects and restrictions of Ondexxya, see the package leaflet.

## Why is Ondexxya authorised in the EU?

On the basis of studies in healthy volunteers and preliminary data from studies in patients, Ondexxya was found effective for reducing antifactor Xa activity in those taking anticoagulants that block factor Xa (factor Xa inhibitors).

The European Medicines Agency noted that it has not been established that antifactor Xa activity can be used as a reliable measure for reduced bleeding and that there was not enough evidence on the use of Ondexxya to reverse the effects of edoxaban, another factor Xa inhibitor.

Patients treated with Ondexxya, especially those aged over 75 years, may be at a higher risk of thromboembolism.

However, the Agency also noted the unmet medical need to stop life-threatening or uncontrolled bleeding caused by factor Xa inhibitors. Furthermore, the data provided, including some data on reduced bleeding, were considered promising. The Agency therefore decided that Ondexxya's benefits are greater than its risks and it can be authorised for use in the EU.

Ondexxya has been given 'conditional authorisation'. This means that there is more evidence to come about the medicine, which the company is required to provide. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Ondexxya?

Since Ondexxya has been given conditional authorisation, the company that markets Ondexxya will provide evidence from studies in patients with major bleeding to reliably link antifactor X activity with the ability to stop bleeding and to clarify the risk of thromboembolism. The company will also carry out studies to gain more information on the effects and blood levels of Ondexxya and to confirm the dosage recommendations.

## What measures are being taken to ensure the safe and effective use of Ondexxya?

Recommendations and precautions to be followed by healthcare professionals for the safe and effective use of Ondexxya have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ondexxya are continuously monitored. Side effects reported with Ondexxya are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ondexxya

Ondexxya received a conditional marketing authorisation valid throughout the EU on 26 April 2019.

Ondexxya : EPAR - Medicine overview

Reference Number: EMA/161566/2019

English (EN) (141.61 KB - PDF)

**First published:** 27/06/2019

[View](/en/documents/overview/ondexxya-epar-medicine-overview_en.pdf)

[Other languages (21)](#file-language-dropdown-673)

български (BG) (144.94 KB - PDF)

**First published:**

27/06/2019

[View](/bg/documents/overview/ondexxya-epar-medicine-overview_bg.pdf)

español (ES) (104.63 KB - PDF)

**First published:**

27/06/2019

[View](/es/documents/overview/ondexxya-epar-medicine-overview_es.pdf)

čeština (CS) (157.72 KB - PDF)

**First published:**

27/06/2019

[View](/cs/documents/overview/ondexxya-epar-medicine-overview_cs.pdf)

dansk (DA) (126.12 KB - PDF)

**First published:**

27/06/2019

[View](/da/documents/overview/ondexxya-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.75 KB - PDF)

**First published:**

27/06/2019

[View](/de/documents/overview/ondexxya-epar-medicine-overview_de.pdf)

eesti keel (ET) (103.01 KB - PDF)

**First published:**

27/06/2019

[View](/et/documents/overview/ondexxya-epar-medicine-overview_et.pdf)

ελληνικά (EL) (148.66 KB - PDF)

**First published:**

27/06/2019

[View](/el/documents/overview/ondexxya-epar-medicine-overview_el.pdf)

français (FR) (105.57 KB - PDF)

**First published:**

27/06/2019

[View](/fr/documents/overview/ondexxya-epar-medicine-overview_fr.pdf)

hrvatski (HR) (124.18 KB - PDF)

**First published:**

27/06/2019

[View](/hr/documents/overview/ondexxya-epar-medicine-overview_hr.pdf)

italiano (IT) (102.64 KB - PDF)

**First published:**

27/06/2019

[View](/it/documents/overview/ondexxya-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (141.17 KB - PDF)

**First published:**

27/06/2019

[View](/lv/documents/overview/ondexxya-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (127.81 KB - PDF)

**First published:**

27/06/2019

[View](/lt/documents/overview/ondexxya-epar-medicine-overview_lt.pdf)

magyar (HU) (136.61 KB - PDF)

**First published:**

27/06/2019

[View](/hu/documents/overview/ondexxya-epar-medicine-overview_hu.pdf)

Malti (MT) (130.12 KB - PDF)

**First published:**

27/06/2019

[View](/mt/documents/overview/ondexxya-epar-medicine-overview_mt.pdf)

Nederlands (NL) (103.65 KB - PDF)

**First published:**

27/06/2019

[View](/nl/documents/overview/ondexxya-epar-medicine-overview_nl.pdf)

polski (PL) (100.97 KB - PDF)

**First published:**

27/06/2019

[View](/pl/documents/overview/ondexxya-epar-medicine-overview_pl.pdf)

português (PT) (114.91 KB - PDF)

**First published:**

27/06/2019

[View](/pt/documents/overview/ondexxya-epar-medicine-overview_pt.pdf)

română (RO) (140.31 KB - PDF)

**First published:**

27/06/2019

[View](/ro/documents/overview/ondexxya-epar-medicine-overview_ro.pdf)

slovenščina (SL) (124.16 KB - PDF)

**First published:**

27/06/2019

[View](/sl/documents/overview/ondexxya-epar-medicine-overview_sl.pdf)

Suomi (FI) (102.67 KB - PDF)

**First published:**

27/06/2019

[View](/fi/documents/overview/ondexxya-epar-medicine-overview_fi.pdf)

svenska (SV) (114.72 KB - PDF)

**First published:**

27/06/2019

[View](/sv/documents/overview/ondexxya-epar-medicine-overview_sv.pdf)

Ondexxya : EPAR - Risk-management plan summary

English (EN) (624.24 KB - PDF)

**First published:** 25/07/2025

[View](/en/documents/rmp-summary/ondexxya-epar-risk-management-plan-summary_en.pdf-0)

## Product information

Ondexxya : EPAR - Product Information

English (EN) (501.12 KB - PDF)

**First published:** 27/06/2019

**Last updated:** 14/11/2025

[View](/en/documents/product-information/ondexxya-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-472)

български (BG) (1.38 MB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/bg/documents/product-information/ondexxya-epar-product-information_bg.pdf)

español (ES) (423.69 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/es/documents/product-information/ondexxya-epar-product-information_es.pdf)

čeština (CS) (552.91 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/cs/documents/product-information/ondexxya-epar-product-information_cs.pdf)

dansk (DA) (1.6 MB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/da/documents/product-information/ondexxya-epar-product-information_da.pdf)

Deutsch (DE) (479.5 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/de/documents/product-information/ondexxya-epar-product-information_de.pdf)

eesti keel (ET) (1.22 MB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/et/documents/product-information/ondexxya-epar-product-information_et.pdf)

ελληνικά (EL) (563.06 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/el/documents/product-information/ondexxya-epar-product-information_el.pdf)

français (FR) (1.2 MB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/fr/documents/product-information/ondexxya-epar-product-information_fr.pdf)

hrvatski (HR) (1.25 MB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/hr/documents/product-information/ondexxya-epar-product-information_hr.pdf)

íslenska (IS) (553.92 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/is/documents/product-information/ondexxya-epar-product-information_is.pdf)

italiano (IT) (498.68 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/it/documents/product-information/ondexxya-epar-product-information_it.pdf)

latviešu valoda (LV) (1.22 MB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/lv/documents/product-information/ondexxya-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.23 MB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/lt/documents/product-information/ondexxya-epar-product-information_lt.pdf)

magyar (HU) (528.74 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/hu/documents/product-information/ondexxya-epar-product-information_hu.pdf)

Malti (MT) (1.57 MB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/mt/documents/product-information/ondexxya-epar-product-information_mt.pdf)

Nederlands (NL) (406.78 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/nl/documents/product-information/ondexxya-epar-product-information_nl.pdf)

norsk (NO) (450.91 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/no/documents/product-information/ondexxya-epar-product-information_no.pdf)

polski (PL) (1.31 MB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/pl/documents/product-information/ondexxya-epar-product-information_pl.pdf)

português (PT) (1.24 MB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/pt/documents/product-information/ondexxya-epar-product-information_pt.pdf)

română (RO) (542.09 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/ro/documents/product-information/ondexxya-epar-product-information_ro.pdf)

slovenčina (SK) (618.59 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/sk/documents/product-information/ondexxya-epar-product-information_sk.pdf)

slovenščina (SL) (541.17 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/sl/documents/product-information/ondexxya-epar-product-information_sl.pdf)

Suomi (FI) (401.94 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/fi/documents/product-information/ondexxya-epar-product-information_fi.pdf)

svenska (SV) (441.42 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

14/11/2025

[View](/sv/documents/product-information/ondexxya-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000304332 14/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ondexxya : EPAR - All authorised presentations

English (EN) (34.99 KB - PDF)

**First published:** 27/06/2019

**Last updated:** 30/05/2023

[View](/en/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-93)

български (BG) (37.32 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/bg/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_bg.pdf)

español (ES) (28.11 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/es/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_es.pdf)

čeština (CS) (36.84 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/cs/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (36.4 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/da/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (30.11 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/de/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (34.87 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/et/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (29.96 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/el/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_el.pdf)

français (FR) (28.21 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/fr/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (35.89 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/hr/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (36.21 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/is/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_is.pdf)

italiano (IT) (28.14 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/it/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.02 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/lv/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (35.88 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/lt/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (35.73 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/hu/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (36.33 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/mt/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (31.26 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/nl/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (36.86 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/no/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_no.pdf)

polski (PL) (30.08 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/pl/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_pl.pdf)

português (PT) (35.99 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/pt/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_pt.pdf)

română (RO) (28.73 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/ro/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (29.83 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/sk/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (35.27 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/sl/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (34.71 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/fi/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (34.99 KB - PDF)

**First published:**

27/06/2019

**Last updated:**

30/05/2023

[View](/sv/documents/all-authorised-presentations/ondexxya-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ondexxya Active substance andexanet alfa International non-proprietary name (INN) or common name andexanet alfa Therapeutic area (MeSH) Drug-Related Side Effects and Adverse Reactions Anatomical therapeutic chemical (ATC) code V03AB

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

## Authorisation details

EMA product number EMEA/H/C/004108

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

AstraZeneca AB

SE-151 85 Sodertalje

Opinion adopted 28/02/2019 Marketing authorisation issued 26/04/2019 Revision 20

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ondexxya : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (143.31 KB - PDF)

**First published:** 15/10/2025

**Last updated:** 14/11/2025

[View](/en/documents/procedural-steps-after/ondexxya-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ondexxya : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (232.61 KB - PDF)

**First published:** 21/08/2019

**Last updated:** 15/10/2025

[View](/en/documents/procedural-steps-after/ondexxya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Ondexxya-PSUSA-00010764-202410  : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMADOC-1700519818-2223305

English (EN) (145.22 KB - PDF)

**First published:** 15/10/2025

[View](/en/documents/scientific-conclusion/ondexxya-psusa-00010764-202410-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

Ondexxya : EPAR - Public assessment report

Adopted

Reference Number: EMA/347546/2019

English (EN) (3.64 MB - PDF)

**First published:** 27/06/2019

[View](/en/documents/assessment-report/ondexxya-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ondexxya

Adopted

Reference Number: EMA/CHMP/40684/2019

English (EN) (83.81 KB - PDF)

**First published:** 01/03/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ondexxya_en.pdf)

#### News on Ondexxya

[First antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban](/en/news/first-antidote-reversal-anticoagulation-factor-xa-inhibitors-apixaban-and-rivaroxaban) 01/03/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019) 01/03/2019

#### More information on Ondexxya

- [EMEA-001902-PIP01-15-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001902-pip01-15-m04)
- [Ondexxya - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/ondexxya)
- [Ondexxya - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/ondexxya-0)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 14/11/2025

## Share this page

[Back to top](#main-content)